scholarly journals Oral administration of Bifidobacterium breve B-3 modifies metabolic functions in adults with obese tendencies in a randomised controlled trial

2015 ◽  
Vol 4 ◽  
Author(s):  
Jun-ichi Minami ◽  
Shizuki Kondo ◽  
Naotake Yanagisawa ◽  
Toshitaka Odamaki ◽  
Jin-zhong Xiao ◽  
...  
Keyword(s):  
Fat Mass ◽  
Controlled Trial ◽  
High Sensitivity ◽  
Blood Parameters ◽  
Double Blind ◽  
Bifidobacterium Breve ◽  
Reactive Protein ◽  
Diet Induced Obesity ◽  
Metabolic Functions ◽  
Randomised Controlled

AbstractAccumulating evidence suggests an association between gut microbiota and the development of obesity, raising the possibility of probiotic administration as a therapeutic approach. Bifidobacterium breve B-3 was found to exhibit an anti-obesity effect on high-fat diet-induced obesity mice. In the present study, a randomised, double-blind, placebo-controlled trial was conducted to evaluate the effect of the consumption of B. breve B-3 on body compositions and blood parameters in adults with a tendency for obesity. After a 4-week run-in period, the participants were randomised to receive either placebo or a B-3 capsule (approximately 5 × 1010 colony-forming units of B-3/d) daily for 12 weeks. A significantly lowered fat mass was observed in the B-3 group compared with the placebo group at week 12. Improvements were observed for some blood parameters related to liver functions and inflammation, such as γ-glutamyltranspeptidase and high-sensitivity C-reactive protein. Significant correlations were found between the changed values of some blood parameters and the changed fat mass in the B-3 group. These results suggest the beneficial potential of B. breve B-3 in improving metabolic disorders.

scholarly journals Effect of Periodontal Treatment on HbA1c among Patients with Prediabetes

2018 ◽  
Vol 98 (2) ◽  
pp. 171-179 ◽  
Author(s):  
T. Kocher ◽  
B. Holtfreter ◽  
A. Petersmann ◽  
P. Eickholz ◽  
T. Hoffmann ◽  
...  
Keyword(s):  
Controlled Trial ◽  
High Sensitivity ◽  
Periodontal Treatment ◽  
Double Blind Study ◽  
Double Blind ◽  
Reactive Protein ◽  
Probing Depth ◽  
Multicenter Randomized Controlled Trial ◽  
Post Hoc ◽  
Observation Period

Evidence is limited regarding whether periodontal treatment improves hemoglobin A1c (HbA1c) among people with prediabetes and periodontal disease, and it is unknown whether improvement of metabolic status persists >3 mo. In an exploratory post hoc analysis of the multicenter randomized controlled trial “Antibiotika und Parodontitis” (Antibiotics and Periodontitis)—a prospective, stratified, double-blind study—we assessed whether nonsurgical periodontal treatment with or without an adjunctive systemic antibiotic treatment affects HbA1c and high-sensitivity C-reactive protein (hsCRP) levels among periodontitis patients with normal HbA1c (≤5.7%, n = 218), prediabetes (5.7% < HbA1c < 6.5%, n = 101), or unknown diabetes (HbA1c ≥ 6.5%, n = 8) over a period of 27.5 mo. Nonsurgical periodontal treatment reduced mean pocket probing depth by >1 mm in both groups. In the normal HbA1c group, HbA1c values remained unchanged at 5.0% (95% CI, 4.9% to 6.1%) during the observation period. Among periodontitis patients with prediabetes, HbA1c decreased from 5.9% (95% CI, 5.9% to 6.0%) to 5.4% (95% CI, 5.3% to 5.5%) at 15.5 mo and increased to 5.6% (95% CI, 5.4% to 5.7%) after 27.5 mo. At 27.5 mo, 46% of periodontitis patients with prediabetes had normal HbA1c levels, whereas 47.9% remained unchanged and 6.3% progressed to diabetes. Median hsCRP values were reduced in the normal HbA1c and prediabetes groups from 1.2 and 1.4 mg/L to 0.7 and 0.7 mg/L, respectively. Nonsurgical periodontal treatment may improve blood glucose values among periodontitis patients with prediabetes (ClinicalTrials.gov NCT00707369).

scholarly journals Pengaruh Pemberian N-Acetylcysteine Oral terhadap High Sensitivity C Reactive Protein (Hs-CRP) pada Pasien Hemodialisis Kronis

2017 ◽  
Vol 2 (4) ◽  
pp. 228
Author(s):  
Ratih Tri Kusuma Dewi ◽  
Parlindungan Siregar ◽  
Idrus Alwi ◽  
Cleopas Martin Rumende
Keyword(s):  
Cardiovascular Event ◽  
Controlled Trial ◽  
High Sensitivity ◽  
P Value ◽  
C Reactive Protein ◽  
Double Blind ◽  
Reactive Protein ◽  
Hs Crp

Pendahuluan. Inflamasi dan stres oksidatif merupakan faktor risiko penyakit kardiovaskuler pada pasien penyakit ginjal kronis yang menjalani hemodialisis. Pasien hemodialisis kronis akan mengalami peningkatan kadar Hs-CRP. Hs-CRP merupakan marker inflamasi yang telah terbukti pada beberapa penelitian bermanfaat dalam memprediksi cardiovascular event. Pemberian N-Acetylcysteine (NAC) oral dapat digunakan sebagai strategi untuk menurunkan proses inflamasi yaitu disfungsi endotel dan stress oksidatif yang berperan pada atherosclerosis pada pasien hemodialsis. Pemberian NAC ini diharapkan dapat menurunkan angka morbiditas dan mortalitas karena penyakit kardiovaskuler.Metode. Penelitian eksperimen dengan Randomized Double Blind Controlled Trial pada 65 pasien hemodialisis kronis yang memenuhi kriteria inklusi di unit hemodialisis RS.Cipto Mangunkusumo Jakarta. Penelitian dilakukan pada Agustus sampai Oktober 2013Hasil. Perlakuan dengan NAC oral selama 60 hari tidak memberikan perbedaan dibandingkan dengan plasebo. Analisis statistik dengan Mann Whitney menunjukkan bahwa tidak ada penurunan kadar Hs-CRP yang signifikan diantara kedua kelompok dengan p value Δ post1-baseline, Δ post2-baseline, and Δ post2-post1 kelompok NAC dibanding kelompok plasebo secara berurutan yaitu 0.796, 0.379 dan 0.712. Sementara itu, hasil uji Wilcoxon Signed Ranks untuk membandingkan penurunan kadar Hs-CRP pada tiap kelompok dalam tiga interval pengukuran Hs-CRP menunjukkan p value dari perbandingan kadar Hs-CRP untuk masing-masing kelompok baseline:Post1, baseline:Post2 dan Post1:Post2 (kelompok NAC Vs kelompok plasebo) secara berurutan 0.821vs0.651; 0.845vs0.358 dan 0.905vs0.789.Simpulan. Pemberian N-Acetylcysteine oral belum terbukti dapat menurunkan kadar Hs-CRP pada pasien hemodialisis kronis.

scholarly journals Sex May Modulate the Effects of Combined Polyphenol Extract and L-citrulline Supplementation on Ambulatory Blood Pressure in Adults with Prehypertension: A Randomized Controlled Trial

Nutrients ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 399
Author(s):  
Cécile Vors ◽  
Maryka Rancourt-Bouchard ◽  
Charles Couillard ◽  
Iris Gigleux ◽  
Patrick Couture ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Blood Lipids ◽  
Vascular Dysfunction ◽  
Controlled Trial ◽  
High Sensitivity ◽  
Potential Interaction ◽  
Double Blind ◽  
Reactive Protein ◽  
The Difference ◽  
Hs Crp

Increased blood pressure (BP), vascular dysfunction and inflammation are involved in the etiology of cardiovascular disease (CVD). Although several dietary components such as polyphenols and L-citrulline may help to control BP, their combined impact on ambulatory BP in individuals at risk of CVD remains unknown. The objective of this research was to investigate the short-term impact of supplementation with a combination of polyphenol extract and L-citrulline on ambulatory BP, endothelial function and inflammation. In a randomized double-blind parallel trial, 73 men and women with prehypertension were supplemented with a placebo (cellulose, n = 34, Plac) or 548 mg/day of polyphenols and 2 g/day of L-citrulline (n = 35, Suppl) for 6 weeks. The primary outcome of this study was the difference between groups in 24-h ambulatory diastolic BP (DBP) at week six. Secondary outcomes were a difference between groups at week six in ambulatory systolic BP (SBP), casual BP, serum lipids and high-sensitivity C-reactive protein (hs-CRP) concentrations and skin advanced glycation end products (AGEs). Potential interaction of treatment with sex was examined. Suppl had no impact on mean ambulatory SBP and DBP (p > 0.10 vs. placebo). Daytime and 24-h SBP were reduced with Suppl in women (p ≤ 0.01), but not in men (p ≥ 0.27). A non-significant reduction in AGEs was observed after Suppl compared to Plac among all participants (p = 0.07) and there was no difference in the concentrations of blood lipids (p > 0.20) or CRP (p = 0.36) between treatments at week six. Therefore, supplementation with polyphenol extract and L-citrulline for 6 weeks has no impact on ambulatory BP, blood lipids and CRP in adults with prehypertension. However, the polyphenol extract/L-citrulline supplement may reduce ambulatory SBP in women, but not in men. These preliminary results need further research efforts towards further documenting this sex-dependent BP response to supplementation with polyphenols and L-citrulline.

scholarly journals Protocol for the insight study: a randomised controlled trial of single-dose tocilizumab in patients with depression and low-grade inflammation

BMJ Open ◽  
2018 ◽  
Vol 8 (9) ◽  
pp. e025333 ◽  
Author(s):  
Golam M Khandaker ◽  
Bianca P Oltean ◽  
Muzaffer Kaser ◽  
Claire R M Dibben ◽  
Rajini Ramana ◽  
...  
Keyword(s):  
Controlled Trial ◽  
High Sensitivity ◽  
International Classification Of Diseases ◽  
Controlled Clinical Trial ◽  
Low Grade ◽  
Double Blind ◽  
South Central ◽  
Hs Crp ◽  
Randomised Controlled ◽  
Low Grade Inflammation

IntroductionObservational studies indicate a potentially causal role for interleukin 6 (IL-6), a proinflammatory cytokine, in pathogenesis of depression, but interventional studies based on patients with depression have not been conducted. Tocilizumab, anti-inflammatory drug, is a humanised monoclonal antibody that inhibits IL-6 signalling and is licensed in the UK for treatment of rheumatoid arthritis. The main objectives of this study are to test whether IL-6 contributes to the pathogenesis of depression and to examine potential mechanisms by which IL-6 affects mood and cognition. A secondary objective is to compare depressed participants with and without evidence of low-grade systemic inflammation.Methods and analysisThis is a proof-of-concept, randomised, parallel-group, double-blind, placebo-controlled clinical trial. Approximately 50 participants with International Classification of Diseases 10th revision (ICD-10) diagnosis of depression who have evidence of low-grade inflammation, defined as serum high-sensitivity C reactive protein (hs-CRP) level ≥3 mg/L, will receive either a single intravenous infusion of tocilizumab or normal saline. Blood samples, behavioural and cognitive measures will be collected at baseline and after infusion around day 7, 14 and 28. The primary outcome is somatic symptoms score around day 14 postinfusion. In addition, approximately, 50 depressed participants without low-grade inflammation (serum hs-CRP level <3 mg/L) will complete the same baseline assessments as the randomised cohort.Ethics and disseminationThe study has been approved by the South Central—Oxford B Research Ethics Committee (REC) (Reference: 18/SC/0118). Study findings will be published in peer-review journals. Findings will be also disseminated by conference/departmental presentations and by social and traditional media.Trial registration numberISRCTN16942542; Pre-results.

scholarly journals Infant formula containing galacto-and fructo-oligosaccharides and Bifidobacterium breve M-16V supports adequate growth and tolerance in healthy infants in a randomised, controlled, double-blind, prospective, multicentre study

2016 ◽  
Vol 5 ◽  
Author(s):  
M. Abrahamse-Berkeveld ◽  
M. Alles ◽  
E. Franke-Beckmann ◽  
K. Helm ◽  
R. Knecht ◽  
...  
Keyword(s):  
Weight Gain ◽  
Adverse Events ◽  
Blood Parameters ◽  
Daily Weight Gain ◽  
Control Group ◽  
Double Blind ◽  
Term Infants ◽  
Bifidobacterium Breve ◽  
Randomised Controlled ◽  
Hydrolysed Formula

AbstractThe objective of the present study was to evaluate the growth and tolerance in healthy, term infants consuming a synbiotic formula with daily weight gain as the primary outcome. In a randomised, controlled, double-blind, multicentre, intervention study infants were assigned to an extensively hydrolysed formula containing a specific combination of Bifidobacterium breve M-16V and a prebiotic mixture (short-chain galacto-oligosaccharides and long-chain fructo-oligosaccharides in a 9:1 ratio; scGOS/lcFOS; synbiotic group), or the same formula without this synbiotic concept for 13 weeks (control group). Anthropometry, formula intake, tolerance, stool characteristics, blood parameters, faecal microbiota and metabolic faecal profile were assessed. Medically confirmed adverse events were recorded throughout the study. Equivalence in daily weight gain was demonstrated for the intention-to-treat (ITT) population (n 211). In the per-protocol (PP) population (n 102), the 90 % CI of the difference in daily weight gain slightly crossed the lower equivalence margin. During the intervention period, the mean weight-for-age and length-for-age values were close to the median of the WHO growth standards in both groups, indicating adequate growth. The number of adverse events was not different between both groups. No relevant differences were observed in blood parameters indicative for liver and renal function. At 13 weeks, an increased percentage of faecal bifidobacteria (60 v. 48 %) and a reduced percentage of Clostridium lituseburense/C. histolyticum (0·2 v. 2·6 %) were observed in the synbiotic group (n 19) compared with the control group (n 27). In conclusion, this study demonstrates that an extensively hydrolysed formula with B. breve M-16V and the prebiotic mixture scGOS/lcFOS (9:1) supports an adequate infant growth.

Sign in / Sign up

Export Citation Format

Share Document